These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15985000)

  • 21. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 22. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.
    Ouzan D; Pénaranda G; Joly H; Halfon P
    J Hepatol; 2013 Jun; 58(6):1258-9. PubMed ID: 23318602
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon alfa, peginterferon alfa and retinopathy.
    Prescrire Int; 2006 Apr; 15(82):61-2. PubMed ID: 16607695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
    Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pegylated alfa-2a in hepatitis B. Fewer injections with better results?].
    MMW Fortschr Med; 2003 Nov; 145(48):63. PubMed ID: 14725009
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
    Orlent H
    N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16224825
    [No Abstract]   [Full Text] [Related]  

  • 29. Persistence with hepatitis C therapy in the Department of Veterans Affairs.
    Iqbal SU; Cunningham F; Lee A; Miller DR; Li NC; Cheung R; Kazis L
    J Clin Pharm Ther; 2008 Jun; 33(3):251-61. PubMed ID: 18452412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.
    Pockros PJ; Carithers R; Desmond P; Dhumeaux D; Fried MW; Marcellin P; Shiffman ML; Minuk G; Reddy KR; Reindollar RW; Lin A; Brunda MJ;
    Am J Gastroenterol; 2004 Jul; 99(7):1298-305. PubMed ID: 15233669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
    Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
    J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference?
    Sierra F
    J Hepatol; 2007 Feb; 46(2):349; author reply 349-50. PubMed ID: 17161495
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pegasys: FDA approved Pegasys (peginterferon alfa-2a) for the treatment of hepatitis C].
    Iafolla M
    Sidahora; 2002; (4):8-10. PubMed ID: 12703472
    [No Abstract]   [Full Text] [Related]  

  • 35. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.
    Brennan BJ; Lemenuel-Diot A; Snoeck E; McKenna M; Solsky J; Wat C; Mallalieu NL
    Br J Clin Pharmacol; 2016 Apr; 81(4):658-66. PubMed ID: 26529640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Injection site with generalized rash caused by pegylated interferon alpha 2a injection.
    Kawada K; Maeda N; Kobayashi S; Sowa J; Tsuruta D; Kawada N
    Dermatology; 2006; 212(1):82-3. PubMed ID: 16319482
    [No Abstract]   [Full Text] [Related]  

  • 39. HIV & hepatitis C: treatment.
    WORLD; 2002 May; (133):4-5. PubMed ID: 12064298
    [No Abstract]   [Full Text] [Related]  

  • 40. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
    J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.